It has been a busy few months for the QUARTET project. Site RTQA approvals and individual case reviews of radiotherapy treatment plans for patients in the FaR-RMS (EpSSG), HRMB (SIOP Europe Brain Tumour Group), HR-NBL2 (SIOPEN), and LINES (SIOPEN) are ongoing – with around 150 site approvals across 22 countries and over 500 patient reviews completed. We are currently working with the radiotherapy committees from the trials and European Clinical Trial Study Groups to review common causes of error and producing extra resources and guideline updates to better support centres to deliver high quality radiotherapy for children and adolescents.
On the 16 November 2023, QUARTET held its annual meeting in Brussels. We discussed all the latest progress on research projects, current and planned trials, and future directions for QUARTET. We were pleased to have a good turnout with sponsor representatives, reviewers, study leads, past fellows. and research collaborators all participating in the meeting.
Over the last few months, QUARTET presented work at SIOP 2023, the EpSSG Winter Meeting 2023, and contributed to a special paediatric radiotherapy education session at the Romanian Society for Radiation and Medical Oncology congress in Cluj Napoca. In 2023, QUARTET contributed to six published manuscripts and six conference abstracts. We hope to continue this strong engagement into 2024 and will keep the community informed of our progress.
As always, more information can be found on the QUARTET website, including an updated list and links to all our publications and other outputs of interest.
